Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Background/Purpose: Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk. In 2010, the ACR developed recommendations for the prevention…Abstract Number: 830 • 2015 ACR/ARHP Annual Meeting
Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis
Background/Purpose: Calcinosis is a debilitating complication of systemic sclerosis (SSc). We sought to determine the clinical factors associated with calcinosis in an international multi-center collaborative…Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…Abstract Number: 2509 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid Induced Osteoporosis Screening and Treatment: A Gender Comparison in a Cohort of Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Background/Purpose: One-fourth of hip fractures occur in men. Men treated with oral glucocorticoids for at least 3 months are particularly at risk. Studies have suggested…Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…Abstract Number: 916 • 2014 ACR/ARHP Annual Meeting
Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density
Background/Purpose: We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone…Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…Abstract Number: 111 • 2014 ACR/ARHP Annual Meeting
Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy
Background/Purpose Aromatase inhibitors (AI) are increasingly used as adjuvant hormonal therapy in postmenopausal women with estrogen receptor-positive breast cancer. It is well recognized that therapy…Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting
Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study
Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…Abstract Number: 2314 • 2014 ACR/ARHP Annual Meeting
Dexa Testing in Long-Term Steroid Use
Background/Purpose: Risk stratification in the ACR glucocorticoid-induced osteoporosis guidelines includes DEXA testing, which is not universally implemented at our rheumatology clinic. DEXA utilization should be…Abstract Number: 2315 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Background/Purpose: One-fourth of hip fractures occur in men. Three groups of men are at high risk for fracture: those who have already suffered a fragility…